Canadian Sec - Delayed Quote CAD

BioNxt Solutions Inc. (BNXT.CN)

0.2600 0.0000 (0.00%)

At close: November 3 at 11:35:37 AM EST

BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate

ACCESS Newswire 15d ago

BNXT.CN
0.00%
BXT.F

BNXTF
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

ACCESS Newswire 2mo ago

BNXT.CN
0.00%
BXT.F

BNXTF
BioNxt Solutions Announces Option Grants

ACCESS Newswire 3mo ago

BNXT.CN
0.00%
BXT.F

BNXTF
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway

ACCESS Newswire 3mo ago

BNXT.CN
0.00%
BXT.F

BNXTF
BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

ACCESS Newswire 4mo ago

BNXT.CN
0.00%
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

ACCESS Newswire 4mo ago

BNXT.CN
0.00%
MRK.DE

BXT.F
BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

ACCESS Newswire 4mo ago

BNXT.CN
0.00%
BXT.F

BNXTF
BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

ACCESS Newswire 4mo ago

BNXT.CN
0.00%
BNXTF

BXT.F
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

ACCESS Newswire 5mo ago

BNXT.CN
0.00%
BNXTF

BXT.F
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

ACCESS Newswire 6mo ago

BNXT.CN
0.00%
BNXTF

BXT.F
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

ACCESS Newswire 6mo ago

BNXT.CN
0.00%
BNXTF
BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study

ACCESS Newswire 1mo ago

BXT

BNXTF

BNXT.CN
0.00%

U.S. markets open in 9h 19m

BioNxt Solutions Inc. (BNXT.CN)

BioNxt Completes GMP Manufacturing and Submits Clinical Trial Application for Sublingual Cladribine Drug Candidate

BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline

BioNxt Solutions Announces Option Grants

BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway

BioNxt Announces Closing of Non-brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

BioNxt Announces Non-Brokered Private Placement of Units Pursuant to the Listed Issuer Exemption

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)

BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study